Results 51 to 60 of about 507,510 (307)

Use of laboratory-developed assays in global HIV-1 treatment-monitoring and research

Scientific Reports, 2023
There has been a surge in the emergence of HIV-1 drug resistance in Low and Middle-Income Countries (LMICs) due to poor drug-adherence and limited access to viral load testing, the current standard for treatment-monitoring.
Jemima Malisa, Mark Manak, Clive Michelo, Nesrina Imami, Catherine N. Kibirige   +4 more
doaj   +1 more source

Drug sensitivity, drug-resistant mutations, and structures of three conductance domains of viral porins

Biochimica et Biophysica Acta (BBA) - Biomembranes, 2011
Recent controversies associated with the structure of the M2 protein from influenza A virus and the binding site of drug molecules amantadine and rimantadine motivated the comparison here of the drug binding to three viral porins including the M2 proteins from influenza A and B as well as the viral protein 'u' from HIV-1.
Sharma, Mukesh, Li, Conggang, Busath, David D., Zhou, Huan-Xiang, Cross, Timothy A.   +4 more
openaire   +2 more sources

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Isolation of poliovirus 2C mutants defective in viral RNA synthesis [PDF]

, 1988
Two poliovirus mutants were isolated that contain an oligonucleotide linker insertion in the 2C-coding region of the viral genome. One, 2C-31, has a strongly temperature-sensitive phenotype and the other, 2C-32, forms small plaques on HeLa cell ...
Baltimore, David, Li, Jing-Po
core  

The Infectious Disease Ontology in the Age of COVID-19 [PDF]

, 2021
The Infectious Disease Ontology (IDO) is a suite of interoperable ontology modules that aims to provide coverage of all aspects of the infectious disease domain, including biomedical research, clinical care, and public health.
Babcock, Shane, Beverley, John, Cowell, Lindsay G., Smith, Barry   +3 more
core   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Subtype diversity and emergence of drug resistance in HIV-1 in solapur district of Maharashtra, India

Iranian Journal of Microbiology, 2022
Background and Objectives: Even after four decades, HIV infection remains a global challenge and a leading cause of mortality in adults across the world.
Dilip D. Karad, Ravi Tandon, Ajay Arya, Kailash D. Sonawane, Anusaya S. Chavan, Arun S. Kharat   +5 more
doaj  

Impact of early initiation versus national standard of care of antiretroviral therapy in Swaziland's public sector health system : study protocol for a stepped-wedge randomized trial [PDF]

, 2017
Background: There is robust clinical evidence to support offering early access to antiretroviral treatment (ART) to all HIV-positive individuals, irrespective of disease stage, to both improve patient health outcomes and reduce HIV incidence. However, as
Barnighausen, Till, Delva, Wim, Fleming, Yvette, Khumalo, Gavin, Lejeune, Charlotte L, Mazibuko, Sikhathele, Mlambo, Charmaine Khudzie, Okello, Velephi, Reis, Ria, Spiegelman, Donna, Walsh, Fiona J, Zwane, Mandisa   +11 more
core   +5 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Antiretroviral Drug Resistance Mutations among HIV Treatment Failure Patients in Tehran, Iran

Iranian Journal of Public Health, 2017
Background: This study aimed to determine drug resistance mutations in patients with virological failure and find correlation between HIV drug resistance test and viral load.
Molood FARROKHI, Samaneh MOALLEMI, Reza SHIRKOOHI, Reza GOLMOHAMMADI, Sara AHSANI-NASAB, Sara SARDASHTI, Ladan ABBASIAN, Kazem BAESI, Minoo MOHRAZ   +8 more
doaj